Form4insider filings, from the source

SEC Form 4 · accession 0001209191-19-002289

Denali Therapeutics Inc. · DNLI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Carole Ho
Officer — Chief Medical Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 6:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF4,F5Jan 2, 2019S4,875$19.43D143,515ISee footnote
Common StockF6,F5Jan 2, 2019S900$20.24D142,615ISee footnote
Common StockF7Jan 3, 2019M5,775$5.28A8,552D
Common StockF8Jan 3, 2019S2,777$18.90D2,777D
Common StockJan 4, 2019M5,950$5.28A8,727D
Common StockF9Jan 4, 2019S1,500$19.30D7,227D
Common StockF10Jan 4, 2019S4,450$20.03D2,777D
Common StockF1holding———46,875D
Common StockF2holding———25,000ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F11$5.28Jan 3, 2019M5,775D—Jul 1, 2026Common Stock5,775108,335D
Stock Option (right to buy)F11$5.28Jan 4, 2019M5,950D—Jul 1, 2026Common Stock5,950102,385D

Explanation of responses